SYSTEMATIC REVIEW

Humanistic burden and economic impact of heart failure – a systematic review of the literature [version 2; peer review: 1 approved, 1 approved with reservations]

Lucia Giles
Caroline Freeman
Polly Field
Elisabeth Sörstadius
Bernt Kartman

1PharmaGenesis Oxford Central, Oxford, UK
2AstraZeneca Gothenburg, Mölndal, Sweden

Abstract
Background: Heart failure (HF) is increasing in prevalence worldwide. This systematic review was conducted to inform understanding of its humanistic and economic burden.

Methods: Electronic databases (Embase, MEDLINE®, and Cochrane Library) were searched in May 2017. Data were extracted from studies reporting health-related quality of life (HRQoL) in 200 patients or more (published 2007–2017), or costs and resource use in 100 patients or more (published 2012–2017). Relevant HRQoL studies were those that used the 12- or 36-item Short-Form Health Surveys, EuroQol Group 5-dimensions measure of health status, Minnesota Living with Heart Failure Questionnaire or Kansas City Cardiomyopathy Questionnaire.

Results: In total, 124 studies were identified: 54 for HRQoL and 71 for costs and resource use (Europe: 25/15; North America: 24/50; rest of world/multinational: 5/6). Overall, individuals with HF reported worse HRQoL than the general population and patients with other chronic diseases. Some evidence identified supports a correlation between increasing disease severity and worse HRQoL. Patients with HF incurred higher costs and resource use than the general population and patients with other chronic conditions. Inpatient care and hospitalizations were identified as major cost drivers in HF.

Conclusions: Our findings indicate that patients with HF experience worse HRQoL and incur higher costs than individuals without HF or patients with other chronic diseases. Early treatment of HF and careful disease management to slow progression and to limit the requirement for hospital admission are likely to reduce both the humanistic burden and economic impact of HF.
Amendments from Version 1

In response to comments from the reviewers we made the following amendments to the manuscript.

Introduction
- Defined humanistic burden as used in the context of this publication
- Included introductory text on the difference between heart failure with reduced ejection fraction and heart failure with preserved ejection fraction
- Introduced the fact that patients with heart failure experience worse health-related quality of life than those with other chronic disease

Methods
- Clarified that the systematic review that informs this manuscript was not prospectively registered with the National Institute for Health Research International Prospective Register of Systematic Reviews (PROSPERO); however, the protocol is available from the corresponding author

Discussion
- Clarified the intention of this review was to provide an overview of the humanistic and economic impact of heart failure that supplements the published literature
- Defined humanistic burden as used in the context of this publication
- Introduced discussion on the limited treatment options available to patients with heart failure with preserved ejection fraction

Conclusions
- Clarified that our findings suggest that both humanistic and economic burden is increased in patients with heart failure compared with patients without heart failure, rather than those with other chronic diseases as there were not sufficient data identified to support this statement
- Discussed the challenges of quantifying the detriment experienced by patients with heart failure from a broad evidence base and provided an overarching assessment of the literature

Any further responses from the reviewers can be found at the end of the article

Introduction
Heart failure (HF) is estimated to affect more than 23 million people worldwide1 and is increasing in prevalence1. Causes of HF include those of cardiac aetiology in addition to chronic diseases such as diabetes mellitus (DM) and chronic kidney disease (CKD)2; HF has been reported as the most common cardiovascular complication of DM2. The growing prevalence of HF can be attributed both to the increasing median age of populations worldwide and to the increasing prevalence of cardiovascular disease, obesity, and DM2. Early treatment of DM could have a significant impact in preventing the development of HF in a proportion of patients, limiting both the humanistic burden, which we consider for the purposes of this review as the effect of HF on the health-related quality of life (HRQoL) of the individuals affected3, and the economic impact of the disease.

HF is chronic and progressive in nature, and can be classified into New York Heart Association (NYHA) classes I–IV based on physical limitation and objective assessment of the presence of cardiovascular disease4 or according to percentage ejection fraction5. The pathophysiology of HF with reduced ejection fraction (HFrEF) differs from that of HF with preserved ejection fraction (HFrEF), with a higher prevalence of non-cardiac morbidities (including DM and hypertension) in patients with HFrEF than in those with HFrEF. Given the differences in aetiology and progression of these diseases4, the economic burden of HFrEF and HFrEF may vary5–10. The signs and symptoms of HF include breathlessness, swelling, fatigue, and fluid retention, which can lead to reduced mobility and impaired daily physical functioning11. Patients may also face psychological problems, such as depression or anxiety, as well as social concerns, especially regarding isolation12. The impact of HF symptoms upon multiple aspects of patients’ lives means that the condition can cause a significant reduction in HRQoL13. Impaired HRQoL in patients with HF compared with those with chronic disease or healthy individuals is well documented14, and directly surveying the patient’s daily wellbeing is key to understanding the impact of disease on their daily life15,16. Both HF-specific and generic HRQoL instruments can be used to measure the effects of HF on patients’ daily lives and well-being16.

Most patients with HF require routine management of their disease1. Treatment typically comprises daily medication as well as periodic visits to primary care providers; however, the most economically costly aspect of the disease is admission to hospital and subsequent inpatient care17. This is often required owing to worsening of symptoms. The acute nature of these occurrences, along with the risk of infection, can mean that patients with HF may be admitted to hospital as an emergency case18, incurring high costs19. Patients are typically treated in the intensive care unit, with clinical stabilization and symptom improvement as the primary focus following admission19. Once a patient’s condition has stabilized, they are likely to be transferred to the ward, and a multidisciplinary approach employed to aid disease management18. Treatment optimization and the management of both cardiovascular and non-cardiovascular comorbidities play a significant role in preventing further hospitalizations, because hospitalization with HF is associated with high rates of readmission16. Outside hospital, many patients with HF receive care in a primary setting or may receive informal care and support in the home, imposing a wider societal cost19.

This systematic review (SR) was conducted to inform understanding of the humanistic burden and economic impact of HF by identifying relevant evidence on HRQoL, costs, and medical resource use in patients with HF.

Methods
Systematic literature review
A systematic search was performed using MEDLINE20 and MEDLINE In-Process, Embase, and the Cochrane Library via Ovid between January 2002 and May 2017 for the humanistic burden SR, and between January 2007 and May 2017 for the economic impact SR. Supplementary searches included reviews of congress abstracts between 2015 and 2017 (or the most recent 2 years available) for the following meetings: International Society for Pharmacoeconomics and Outcomes Research US
and European congresses, American Heart Association Scientific Sessions, European Society of Cardiology (ESC) Congress, World Congress of Cardiology and Cardiovascular Health, American College of Cardiology Annual Scientific Session, and ESC Heart Failure. The search strings used to identify evidence are listed in Table 1. This review was not prospectively registered with the National Institute for Health Research International Prospective Register of Systematic Reviews (PROSPERO), but the protocol is available on request from the corresponding author.

### Citation screening and full text review

Abstracts and titles identified were screened by an independent reviewer to determine whether they met the PICOS (patient, interventions, comparisons, outcomes, and study design) eligibility criteria (Table 2), in accordance with 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All publications that met the entry criteria for the review were obtained as full articles and reassessed against the review criteria. Owing to the large number of citations meeting the predefined inclusion criteria,

#### Table 1. Electronic search strategy.

| # | Searches                                                                                                                                                                                                 | Results  |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 1 | (heart or cardiac or myocard*) adj (fail* or insufficien*),ti,ab. or *heart failure/ or congestive heart failure,ti,ab. or (reduced ejection fraction or HFrEF or preserved ejection fraction or HFpEF or mid range ejection fraction or HFrEF),ti,ab. | 245 779  |
| 2 | pay?r.ti,ab.                                                                                                                                                                                              | 10 875   |
| 3 | (patient reported outcome* or PRO or self reported outcome*),ti,ab.                                                                                                                                       | 226 038  |
| 4 | patient satisfaction,ti,ab.                                                                                                                                                                              | 37 515   |
| 5 | (qol or HRQOL or HRQL),ti,ab.                                                                                                                                                                            | 70 852   |
| 6 | (quality of life or health related quality of life),ti,ab.                                                                                                                                                 | 313 107  |
| 7 | (quality adjusted life year* or QALY),ti,ab.                                                                                                                                                              | 16 234   |
| 8 | (health stat* or health state utility value or HSUV),ti,ab.                                                                                                                                               | 69 092   |
| 9 | disutilit*,ti,ab.                                                                                                                                                                                       | 607      |
| 10 | (EQSD or EQ 5D or EuroQol),ti,ab.                                                                                                                                                                        | 12 502   |
| 11 | (Kansas City Cardiomyopathy Questionnaire or KCCQ),tw.                                                                                                                                                   | 522      |
| 12 | ((short-form adj (6d or “36” or “12”)) or (sf-6d or sf-36 or SF-12),ti,ab.                                                                                                                                | 37 307   |
| 13 | (humanistic adj3 burden),ti,ab.                                                                                                                                                                          | 301      |
| 14 | (humanistic adj3 impact),ti,ab.                                                                                                                                                                          | 52       |
| 15 | ((caregiver or employment or productivity) adj (impact or burden)),ti,ab.                                                                                                                                 | 3872     |
| 16 | or/2-15                                                                                                                                                                                                  | 647 101  |
| 17 | 1 and 16                                                                                                                                                                                                  | 17 442   |
| 18 | limit 17 to yr="2002 -Current"                                                                                                                                                                           | 16 118   |
| 19 | budget impact,ti,ab.                                                                                                                                                                                     | 2307     |
| 20 | (pharmacoeconomic or pharmacoeconomics),ti,ab.                                                                                                                                                            | 6853     |
| 21 | (resource adj (allocation or utili* or us*)),ti,ab.                                                                                                                                                      | 28 797   |
| 22 | (health or medical) adj resource*,ti,ab.                                                                                                                                                                 | 9752     |
| 23 | direct cost*,ti,ab.                                                                                                                                                                                      | 9230     |
| 24 | indirect cost*,ti,ab.                                                                                                                         | 7234     |
| 25 | societal,ti,ab.                                                                                                                               | 22 109   |
| 26 | pay?r.ti,ab.                                                                                                                                                                                              | 10 875   |
| 27 | (healthcare cost or ((cost or costs) adj2 (direct or health or healthcare or treatment or assessment or evaluation or calculation))),ti,ab.                                                                 | 73 973   |
| 28 | economic burden,ti,ab.                                                                                                                        | 11 323   |
### Embase, run on 24 May 2017

| #  | Searches                                                                 | Results  |
|----|--------------------------------------------------------------------------|----------|
| 29 | 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28                  | 145 109  |
| 30 | 1 and 29                                                                  | 3223     |
| 31 | limit 30 to yr="2007 -Current"                                            | 2599     |
| 32 | 18 or 31                                                                  | 17 908   |
| 33 | limit 32 to (human and english language)                                   | 14 641   |
| 34 | (registry or register$ or survey).ti,ab.                                 | 806 771  |
| 35 | (real world or RWE).ti,ab.                                                | 34 706   |
| 36 | observational.ti,ab.                                                      | 179 646  |
| 37 | Prospective.ti,ab.                                                       | 650 349  |
| 38 | longitudinal.ti,ab.                                                      | 241 141  |
| 39 | retrospective.ti,ab.                                                      | 603 592  |
| 40 | (patient record* or medical record*).ti,ab.                              | 143 826  |
| 41 | (electronic health record$ or EHR).ti,ab.                               | 12 184   |
| 42 | (electronic medical record$ or EMR).ti,ab.                              | 26 420   |
| 43 | (dataset$ or data set$).ti,ab.                                           | 171 490  |
| 44 | database.ti,ab.                                                          | 311 441  |
| 45 | (administrat* adj3 claim).ti,ab.                                         | 111      |
| 46 | cohort.ti,ab.                                                            | 598 761  |
| 47 | clinical practice.ti,ab.                                                 | 194 286  |
| 48 | Non-interventional.ti,ab.                                                | 4365     |
| 49 | Real-life.ti,ab.                                                         | 19 613   |
| 50 | or/34-49                                                                 | 3 071 749|
| 51 | (RCT or random* or comparative or double blind).ti,ab.                   | 1 545 188|
| 52 | 50 or 51                                                                 | 4 215 740|
| 53 | 17 and 52                                                                | 7565     |
| 54 | limit 53 to yr="2002 -Current"                                           | 7129     |
| 55 | 31 or 54                                                                 | 9189     |
| 56 | limit 55 to (human and english language)                                 | 7994     |
| 57 | limit 56 to ("conference review" or editorial or "review")              | 744      |
| 58 | 56 not 57                                                                | 7250     |
| 59 | limit 58 to (embryo <first trimester> or infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) | 188      |
| 60 | 58 not 59                                                                | 7062     |

### MEDLINE®, run on 24 May 2017

| #  | Searches                                                                 | Results  |
|----|--------------------------------------------------------------------------|----------|
| 1  | (heart or cardiac or myocard*) adj (fail* or insufficien*)).ti,ab. or *heart failure/ or congestive heart failure.ti,ab. (or (reduced ejection fraction or HFrEF or preserved ejection fraction or HfPEF or mid range ejection fraction or HFrEF).ti,ab. | 168 681  |
| 2  | pay?r.ti,ab.                                                             | 6503     |
| 3  | (patient reported outcome* or PRO or self reported outcome*).ti,ab.      | 159 414  |
| 4  | patient satisfaction.ti,ab.                                             | 27 990   |
| # | Searches                                                                 | Results   |
|---|--------------------------------------------------------------------------|-----------|
| 5 | (qol or HRQOL or HRQL).ti,ab.                                           | 42 835    |
| 6 | (quality of life or health related quality of life).ti,ab.               | 214 490   |
| 7 | (quality adjusted life year* or QALY).ti,ab.                            | 10 344    |
| 8 | (health states utility value or HSUV).ti,ab.                            | 56 791    |
| 9 | disutility*.ti,ab.                                                      | 349       |
| 10| (EQ5D or EQ 5D or EuroQol).ti,ab.                                       | 7324      |
| 11| (Kansas City Cardiomyopathy Questionnaire or KCCQ).tw.                  | 262       |
| 12| (short-form adj (6d or “36” or “12”) or (sf-6d or sf-36 or SF-12)).ti,ab.| 25 620    |
| 13| (humanistic adj3 burden).ti,ab.                                         | 112       |
| 14| (humanistic adj3 impact).ti,ab.                                         | 28        |
| 15| ((caregiver or employment or productivity) adj (impact or burden)).ti,ab.| 2683      |
| 16| or/2-15                                                                 | 457 938   |
| 17| 1 and 16                                                                | 10 213    |
| 18| limit 17 to yr="2002 -Current"                                          | 9048      |
| 19| budget impact.ti,ab.                                                    | 942       |
| 20| (pharmacoeconomic or pharmacoeconomics).ti,ab.                          | 3374      |
| 21| (resource adj (allocation or utili* or us*)).ti,ab.                     | 20 262    |
| 22| ((health or medical) adj resource*).ti,ab.                              | 7393      |
| 23| direct cost*.ti,ab.                                                     | 5908      |
| 24| indirect cost*.ti,ab.                                                   | 4893      |
| 25| societal.ti,ab.                                                         | 18 300    |
| 26| pay?.ti,ab.                                                             | 6503      |
| 27| (healthcare cost or ((cost or costs) adj2 (direct or health or healthcare or treatment or assessment or evaluation or calculation))).ti,ab. | 50 685    |
| 28| economic burden.ti,ab.                                                  | 7229      |
| 29| 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28                | 103 649   |
| 30| 1 and 29                                                                | 1830      |
| 31| limit 30 to yr="2007 -Current"                                          | 1276      |
| 32| 18 or 31                                                                | 9935      |
| 33| limit 32 to (human and english language)                                | 7338      |
| 34| (registry or register$ or survey).ti,ab.                                | 633 426   |
| 35| (real world or RWE).ti,ab.                                              | 23 598    |
| 36| observational.ti,ab.                                                    | 123 430   |
| 37| Prospective.ti,ab.                                                      | 471 676   |
| 38| longitudinal.ti,ab.                                                     | 194 013   |
| 39| retrospective.ti,ab.                                                    | 398 258   |
| 40| (patient record* or medical record*).ti,ab.                            | 94 292    |
| 41| (electronic health record$ or EHR).ti,ab.                              | 9932      |
| 42| (electronic medical record$ or EMR).ti,ab.                             | 13 318    |
| 43| (dataset$ or data set$).ti,ab.                                          | 143 415   |
| 44| database.ti,ab.                                                         | 208 559   |
### MEDLINE®, run on 24 May 2017

| # | Searches                                                                 | Results   |
|---|--------------------------------------------------------------------------|-----------|
| 45 | (administrat* adj3 claim).ti,ab.                                        | 80        |
| 46 | cohort.ti,ab.                                                           | 385 679   |
| 47 | clinical practice.ti,ab.                                                | 142 184   |
| 48 | Non-interventional.ti,ab.                                               | 1635      |
| 49 | Real-life.ti,ab.                                                        | 12 043    |
| 50 | or/34-49                                                                | 2 270 099 |
| 51 | (RCT or random* or comparative or double blind).ti,ab.                  | 1 250 698 |
| 52 | 50 or 51                                                                | 3 213 803 |
| 53 | 17 and 52                                                               | 4374      |
| 54 | limit 53 to yr="2002 -Current"                                          | 3972      |
| 55 | 31 or 54                                                                | 5005      |
| 56 | limit 55 to (human and english language)                                | 3861      |
| 57 | limit 56 to (editorial or "review")                                     | 755       |
| 58 | 56 not 57                                                               | 3106      |
| 59 | limit 58 to "all child (0 to 18 years)"                                 | 200       |
| 60 | 58 not 59                                                               | 2906      |

### Cochrane Library, run on 24 May 2017

| # | Searches                                                                 | Results   |
|---|--------------------------------------------------------------------------|-----------|
| 1 | ((heart or cardiac or myocard*.*) adj (fail* or insufficien*).ti,ab or (heart failure/ or congestive heart failure).ti,ab. or (reduced ejection fraction or HFrEF or preserved ejection fraction or HFpEF or mid range ejection fraction or HFmrEF).ti,ab. | 15 899    |
| 2 | pay?r.ti,ab.                                                            | 528       |
| 3 | (patient reported outcome* or PRO or self reported outcome*).ti,ab.     | 7241      |
| 4 | patient satisfaction.ti,ab.                                             | 6103      |
| 5 | (qol or HRQOL or HRQL).ti,ab.                                           | 10 318    |
| 6 | (quality of life or health related quality of life).ti,ab.               | 41 955    |
| 7 | (quality adjusted life year* or QALY).ti,ab.                            | 2188      |
| 8 | (health stat* or health state utility value or HSUV).ti,ab.              | 4752      |
| 9 | disutilit*.ti,ab.                                                       | 31        |
| 10 | (EQ5D or EQ 5D or EuroQol).ti,ab.                                       | 2651      |
| 11 | (Kansas City Cardiomyopathy Questionnaire or KCCQ).tw.                  | 122       |
| 12 | (short-form adj (6d or "36" or "12") or (sf-6d or sf-36 or SF-12)).ti,ab. | 6560      |
| 13 | (humanistic adj3 burden).ti,ab.                                         | 6         |
| 14 | (humanistic adj3 impact).ti,ab.                                         | 6         |
| 15 | ((caregiver or employment or productivity) adj (impact or burden)).ti,ab. | 419       |
| 16 | or/2-15                                                                | 60 519    |
| 17 | 1 and 16                                                                | 2349      |
| 18 | limit 17 to yr="2002 -Current" [Limit not valid in DARE; records were retained] | 2087      |
| 19 | budget impact.ti,ab.                                                    | 144       |
| 20 | (pharmacoeconomic or pharmacoeconomics).ti,ab.                          | 636       |
| 21 | (resource adj (allocation or utili* or us*)).ti,ab.                     | 1228      |
| 22 | ((health or medical) adj resource*).ti,ab.                              | 523       |
| 23 | direct cost*.ti,ab.                                                     | 682       |
## Cochrane Library, run on 24 May 2017

| #  | Searches                                                                                             | Results |
|----|------------------------------------------------------------------------------------------------------|---------|
| 24 | indirect cost*.ti,ab.                                                                                | 519     |
| 25 | societal.ti,ab.                                                                                       | 1327    |
| 26 | pay?.ti,ab.                                                                                           | 528     |
| 27 | (healthcare cost or ((cost or costs) adj2 (direct or health or healthcare or treatment or assessment or evaluation or calculation))).ti,ab. | 7763    |
| 28 | economic burden.ti,ab.                                                                               | 386     |
| 29 | 19 or 20 or 21 or 22 or 24 or 25 or 26 or 27 or 28                                                   | 10 849  |
| 30 | 1 and 29                                                                                             | 297     |
| 31 | limit 30 to yr="2007 -Current" [Limit not valid in DARE; records were retained]                      | 202     |
| 32 | 18 or 31                                                                                             | 2173    |
| 33 | limit 32 to (human and english language) [Limit not valid in CDSR,ACP Journal Club,DARE,CCTR,CLCMR; records were retained] | 1889    |
| 34 | (registry or register$ or survey).ti,ab.                                                             | 45 254  |
| 35 | (real world or RWE).ti,ab.                                                                           | 2263    |
| 36 | observational.ti,ab.                                                                                 | 10 447  |
| 37 | Prospective.ti,ab.                                                                                  | 116 043 |
| 38 | longitudinal.ti,ab.                                                                                 | 9467    |
| 39 | retrospective.ti,ab.                                                                                 | 11 763  |
| 40 | (patient record* or medical record*).ti,ab.                                                          | 3595    |
| 41 | (electronic health record$ or EHR).ti,ab.                                                           | 422     |
| 42 | (electronic medical record$ or EMR).ti,ab.                                                           | 831     |
| 43 | (dataset$ or data set$).ti,ab.                                                                       | 3527    |
| 44 | database.ti,ab.                                                                                       | 8157    |
| 45 | (administrat* adj3 claim).ti,ab.                                                                    | 5       |
| 46 | cohort.ti,ab.                                                                                         | 26 992  |
| 47 | clinical practice.ti,ab.                                                                             | 9826    |
| 48 | Non-interventional.ti,ab                                                                              | 311     |
| 49 | Real-life.ti,ab.                                                                                    | 1318    |
| 50 | or/34-49                                                                                             | 207 133 |
| 51 | (RCT or random* or comparative or double blind).ti,ab.                                               | 622 944 |
| 52 | 50 or 51                                                                                             | 676 091 |
| 53 | 17 and 52                                                                                             | 2053    |
| 54 | limit 53 to yr="2002 -Current" [Limit not valid in DARE; records were retained]                      | 1819    |
| 55 | 31 or 54                                                                                             | 1913    |
| 56 | limit 55 to (human and english language) [Limit not valid in CDSR,ACP Journal Club,DARE,CCTR,CLCMR; records were retained] | 1685    |
| 57 | limit 56 to (editorial or "review") [Limit not valid in CDSR,ACP Journal Club,DARE,CLCMR,CLHTA,CL EED; records were retained] | 31      |
| 58 | 56 not 57                                                                                             | 1654    |
### Eligibility criteria

| Criteria                | Details                                                                 |
|-------------------------|------------------------------------------------------------------------|
| **Population**          | Patients with HF (either with or without comorbidities)                |
|                         | • Adults (≥18 years old)                                               |
|                         | • NYHA class II–IV                                                     |
|                         | • Preserved, mid-range, or reduced ejection fraction (if mentioned)     |
| **Interventions**       | Any or no intervention                                                 |
| **Outcomes**            | Humanistic burden SR                                                   |
|                         | • HRQoL as measured by generic or condition-specific questionnaires    |
|                         | • Health state utility values (HSUVs) as measured using direct or indirect methods |
|                         | • Mapping algorithms (to allow HSUVs to be estimated from generic or condition-specific measures) |
|                         | • Patient-reported outcomes                                             |
| Economic burden SR      | • Direct costs (including any intervention costs)                       |
|                         | • Indirect/wider societal costs                                        |
|                         | • Total costs                                                          |
|                         | • Resource use                                                         |
|                         | • Cost drivers                                                         |
| **Study design**        | Humanistic burden SR                                                   |
|                         | • Observational or interventional studies                              |
|                         | • The humanistic burden SR identified only publications that reported quality of life outcomes within a study setting or by assessment using a survey (search terms for both observational and interventional studies were implemented) |
| Economic burden SR      | • Should include clear objective to assess costs or resource use       |
| **Date restrictions**   | Humanistic burden SR                                                   |
|                         | • January 2002 to May 2017                                             |
| Economic burden SR      | • January 2007 to May 2017                                             |
| **Language restrictions**| • English only (non-English publications with an English abstract will be considered for inclusion) |
| **Country**             | • Australia, Canada, China, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Norway, Spain, Sweden, UK, USA |

### Restriction criteria

For humanistic burden, the following criteria had to be met:
- Full publications
- A study population of 200 or more patients
- HRQoL measured using at least one of the following instruments:
  - 36-item Short-Form Health Survey (SF-36)
  - 12-item Short-Form Health Survey (SF-12)
  - 5-dimension EuroQol questionnaire (EQ-SD)
  - Minnesota Living with Heart Failure Questionnaire (MLHFQ)
  - Kansas City Cardiomyopathy Questionnaire (KCCQ)
- Observational study design

For cost and resource use, the following criteria had to be met:
- Full publications
- Study population of 100 or more patients
- Observational study design
a decision was made to restrict data extraction from eligible studies. For both SRs, data were extracted only from full publications of observational studies. Data were not extracted if the study population included fewer than 200 patients for the humanistic burden SR, and fewer than 100 patients for the economic impact SR. The restriction criteria used are summarized Table 2.

Data extraction
For each publication, information was extracted into a data-extraction table. For each study, NYHA classification, age, and comorbidities including CKD and DM were recorded.

Results
Search results
In the initial searches, 11,622 papers were identified, of which 2,186 were removed as duplicates, and 9,436 papers were included for electronic screening. Electronic screening identified 8,166 papers that did not meet the inclusion criteria. In total, 124 papers were identified for inclusion following full paper review: 54 papers reporting HRQoL and 71 papers reporting costs and resource use (including one reference that reported data for both outcomes). A PRISMA flow diagram is shown in Figure 1. The studies identified were grouped according to the key data presented, as shown in Figure 2.

Figure 1. PRISMA flow diagram, showing the flow of studies identified through the systematic review process. HRQoL, health-related quality of life. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
**Figure 2.** Summary of evidence identified in this systematic review, showing the number of studies identified, grouped according to the key data presented. HF, heart failure. HRQoL, health-related quality of life. *Some studies reported data that fell into more than one category.*

| Health-related quality of life | Costs and resource use |
|-------------------------------|------------------------|
| **Individuals with and without HF** | **Total costs** |
| 2 studies | 17 studies |
| **Compared with other chronic diseases** | **Individuals with and without HF** |
| 1 study | 5 studies |
| **By disease severity/duration** | **Compared with other chronic diseases** |
| 13 studies | 3 studies |
| **By ejection fraction status** | **As a comorbidity** |
| 2 studies | 4 studies |
| **With comorbidities** | **With comorbidities** |
| 7 studies | 2 studies |
| **Mental health** | **By disease severity** |
| 14 studies | 1 study |
| **Hospitalization** | **By ejection fraction status** |
| 5 studies | 4 studies |
| **Disease management** | **Inpatient care/hospitalization costs** |
| 4 studies | 31 studies |
| **HRQoL as a predictive factor** | **Hospitalization and readmission rates** |
| 8 studies | 44 studies |
| **Sociodemographic status** | **Other costs and resource use** |
| 5 studies | 5 studies |

**HRQoL in patients with and without HF**

A small number of studies assessed HRQoL in patients with HF compared with individuals without HF, or patients with other chronic diseases. In a study conducted in the Netherlands, patients with HF (NYHA class II–IV) reported worse scores across all domains of the 36-item Short-Form Health Survey (SF-36) than a population of age- and sex-matched community control individuals (Figure 3). A Danish study also found that patients who had been discharged from hospital reported lower 12-item Short-Form Health Survey (SF-12) physical component summary (PCS; mean±standard deviation [SD]: 42.5±11.1 vs 47.7±13.4, p<0.001) and mental component summary (MCS; mean±SD: 48.2±10.9 vs 51.5±14.7, p<0.001) scores than a reference group representative of the national population. A further cohort survey, conducted in the UK, compared patients with HF with those who had asthma, chronic obstructive pulmonary disease (COPD), DM, epilepsy, or stroke. Patients with HF reported lower baseline 5-dimension EuroQol questionnaire (EQ-5D) utility and visual analogue scale (VAS) scores than patients with asthma, DM, epilepsy, and stroke, and similar scores to patients with COPD.

**HRQoL by HF severity**

Studies from Sweden, Australia, and the USA assessed HRQoL by NYHA HF class and reported a greater humanistic burden with more severe disease (Figure 4). Based on
Figure 3. SF-36 scores in patients with heart failure compared with the general population. This figure provides a graphical representation of the component scores for the SF-36 HRQoL questionnaire for patients with HF (stage II–IV) compared with community-dwelling elderly people who do not have HF. BP, bodily pain. GHP, general health perception. HF, heart failure. HRQoL, health-related quality of life. MH, mental health. PF, physical functioning. RL-M, role-limiting (mental). RL-P, role-limiting (physical). SF, social functioning. SF-36, 36-item Short-Form Health Survey. V, vitality.

Figure 4. Humanistic burden with increasing New York Heart Association class measured using: (a) MLHFQ, (b) KCCQ, (c) SF-36, and (d) EQ-5D-5L. This figure provides a graphical representation of HRQoL scores by NYHA class as measured by the MLHFQ, KCCQ, SF-36, or EQ-5D-5L questionnaires. Better health-related quality of life is represented by higher KCCQ, SF-36, and EQ-5D-5L scores, and lower MLHFQ scores. EQ-5D-5L, 5-level, 5-dimension EuroQol questionnaire. HFpEF, heart failure with preserved ejection fraction. HFrEF, heart failure with reduced ejection fraction. HRQoL, health-related quality of life. KCCQ, Kansas City Cardiomyopathy Questionnaire. MCS, mental component summary. MLHFQ, Minnesota Living with Heart Failure Questionnaire. NYHA, New York Heart Association. PCS, physical component summary. SF-36, 36-item Short-Form Health Survey.
the evidence identified, there was a reduction in HRQoL between NYHA HF classes I and II, and classes II and III, and between classes III and IV, assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Kansas City Cardiomyopathy Questionnaire (KCCQ), both of which are cardiac-specific instruments. One study also reported decreasing SF-36 PCS and MCS scores with increasing NYHA HF class. For SF-12 scores, there was a greater reduction between NYHA classes I and II, and smaller reductions between more severe NYHA classes (Figure 4). A consistent decrease in utilities between classes II and III (0.042) and classes III and IV (0.041), measured using the 5-level EQ-5D (EQ-5D-5L) was also reported by a single study alongside a decline in MLHFQ scores (Figure 4).

Two further studies, both conducted in the USA, reported a negative correlation between HRQoL and increasing HF severity. A study of patients with HF living in a rural location reported a negative association between NYHA HF class and MLHFQ score, but did not report results by separate NYHA classes. Another study investigated HRQoL in a subgroup of patients with HF as a comorbidity, from a population with CKD in a subanalysis of the Hemodialysis Study, a randomized controlled trial of patients undergoing haemodialysis. Reductions in both mental and physical HRQoL were reported with increasing HF severity (categories ranging from ‘absent’ to ‘severe’). Scores in the role-limiting (physical), bodily pain, general health, vitality, social functioning, and mental health domains, as well as overall PCS scores, decreased with increasing HF severity.

Few longitudinal studies reporting HRQoL in HF were identified. Of the studies that were purely observational, two reported a decrease in HRQoL over time, whereas the remaining three reported an improvement in HRQoL across the study period. A UK cohort study investigating HRQoL in patients with HF relative to those with other chronic diseases reported generic and disease-specific HRQoL scores at baseline and 1 year. Patients with HF were the only group to report a reduction in HRQoL over the follow-up period, with significantly lower EQ-5D VAS scores indicating worse HRQoL at 1 year. A US study reported HRQoL over a follow-up of up to 6.6 years, adjusting for the effect of time on disease deterioration. PCS scores decreased over time, along with scores for six of the eight SF-36 domains; MCS scores and scores for the role-limiting (mental) domain did not decrease over time.

A study in the Netherlands, however, reported that patients with a higher level of education experienced a statistically significant improvement in the role-limiting (emotional) domain of the SF-36 across an 18-month longitudinal study (p=0.015). No significant difference was found in the remaining SF-36 domains. Patients in a Canadian study in whom HF was diagnosed following an emergency department (ED) visit reported increases in physical HRQoL scores over a 12-month period (SF-12 PCS score: 1.6–3.4; KCCQ-physical limitation score: 5.6–9.4). An analysis modelled health trajectories over 12 months defined by patients’ KCCQ scores over time using data from the Patient-Centered Disease Management for Heart Failure trial. Patients with a poor or moderate health status trajectory experienced improvements in KCCQ scores between baseline and 3 months followed by a stabilization in scores up to 12 months, whereas those who had a trajectory of ‘marked improvement’ reported an increase in HRQoL over the whole 12-month period.

In a number of the longitudinal studies identified, healthcare professionals provided support to patients over the follow-up period, which was considered likely to impact HRQoL. These studies are summarized in Extended data: Supplemental Table 1. Studies in Norway and in Spain reported a statistically significant improvement in MLHFQ scores between baseline and 6 or 12 months, respectively, for patients monitored over the study period. In the Spanish study, patients continued to experience an increase in HRQoL over 5 years. An improvement in MLHFQ scores over 12 months following enrolment into an HF clinic was also reported by patients in a Canadian study.

HRQoL in patients with HF by ejection fraction status
Few studies comparing HRQoL in patients with HFrEF and those with HFpEF were identified. In a study conducted in Germany, patients with HFrEF reported better physical functioning, measured using the SF-36, than patients with HFpEF. A study conducted in the USA reported that patients with HFpEF experienced no greater impact on HRQoL than those with HFrEF as disease severity increased. However, patients with HFpEF, with KCCQ scores in the lowest quartile, had a higher risk of mortality or hospitalization as well as lower rates of event-free survival than those who had scores in the highest quartile.

HRQoL in patients with HF and comorbidities
Comorbidities in patients with HF were typically associated with reductions in HRQoL. In studies conducted in Spain and the USA, respectively, patients with HF and iron deficiency or pain reported higher overall and physical summary MLHFQ scores, representative of worse HRQoL, than those without these comorbidities. However, a further study in the USA found that although patients with anaemia reported worse baseline KCCQ scores than those without, deterioration in HRQoL over a 3-month period was similar in both populations. Patients in a study in the Netherlands who experienced difficulties with sexual activity reported worse HRQoL than those without difficulties. In a US study, excessive daytime sleepiness and cognitive impairment were associated with comparatively lower HRQoL. In a second US study, patients who had comparatively lower haemoglobin levels at baseline reported worse KCCQ and MLHFQ scores than those with higher haemoglobin levels.

Patients in Australia, the UK, Ireland, the USA, and Norway who had ischaemic heart disease with ischaemic HF, angina, or a myocardial infarction as a comorbidity reported PCS scores that were lower than expected for the general population (more
than one SD below the standardized mean of the general US population), whereas MCS scores were within one SD of the mean\(^4^\).

**HRQoL and mental health in patients with HF**

Poor mental health was generally associated with worse HRQoL in patients with HF. Comparative studies were identified that focused on depression, suicidal ideation, panic disorder, and distress (Extended data: Supplemental Table 1\(^3^\)).

Patients with HF and depression had worse HRQoL than those without depression in studies from Germany, Italy, and the USA. Statistically significant reductions in scores across all SF-36 domains and the KCCQ summary domains were found with increasing severity of depression in two studies in Germany\(^3\),\(^4\),\(^5\). A further German study reported an association between lower SF-36 physical functioning (PF) and bodily pain scores as severity of depression increased\(^5\). Furthermore, in a study in the USA, PF was negatively correlated with depression\(^6\). Worse health status, as defined by KCCQ score, was associated with a comparatively higher risk of depression at baseline in another US study\(^3\); and a German study indicated that patients with type D personality, predictive of depression, reported worse HRQoL (MLHFQ scores) than those with a different personality type\(^5\).

Suicidal ideation and ideas of self-harm were reported to be associated with reduced HRQoL\(^6\). Patients with panic disorder\(^7\) and those who experienced distress at baseline and/or follow-up\(^2\) reported worse HRQoL than those who did not. Another study reported an association between patients’ end-of-life preferences and their physical HRQoL (SF-36 PCS scores)\(^8\).

Patients’ perceived health status was reported to have a moderate impact on MLHFQ score in a Canadian study\(^8\), and social functioning, measured using the KCCQ, was found to be a predictor of perceived health status, particularly in male patients with HF in the USA\(^6\). High levels of self-care were associated with better MLHFQ or KCCQ scores in studies in Italy\(^6^\),\(^7\), and the USA\(^6\), respectively, as well as lower hospitalization rates in the Italian study.

**Hospitalization and HRQoL in patients with HF**

Patients hospitalized for HF experienced comparatively better HRQoL once discharged from hospital (Extended data: Supplemental Table 1\(^3^\)). A study in the USA and Canada found that EQ-5D scores were higher at the time of hospital discharge than when patients were admitted to hospital (baseline), and remained higher than baseline 30 days after discharge from hospital\(^8\). Another US study showed that MLHFQ scores improved significantly during the first month post-discharge (p<0.001)\(^8\). Furthermore, patients in a study in the USA who did not experience readmission to hospital within 30 days of discharge experienced better HRQoL (KCCQ scores) than those who did\(^8\). Fear of hospitalization had a negative impact on patients’ MLHFQ scores in an Italian study\(^8\), and unplanned hospitalization was identified as a predictor of better SF-12 PCS scores in a patient population who had previously been hospitalized for HF in a study in Denmark\(^2\).

**Impact of disease management on HRQoL in patients with HF**

Owing to the chronic nature of HF, the implementation of appropriate disease management is an important part of treatment, and evidence identified in this SR indicates that it is associated with HRQoL improvements (Extended data: Supplemental Table 1\(^3^\)). Patients in the UK\(^6\) and Germany\(^6\) with HF and either atrial fibrillation or sinus rhythm reported an improvement in HRQoL following cardiac resynchronization therapy and treatment with β-blockers, respectively. The use of left ventricular assist devices (LVADs) as bridging or destination therapy was also associated with an improvement in HRQoL in a US study\(^6\), and patients with an LVAD had better HRQoL than patients assessed for, or awaiting, heart transplant in a UK study\(^8\).

**HRQoL as a predictive factor in patients with HF**

Several studies were identified that reported HRQoL as a predictive factor both of mortality and of outcomes in patients with HF (Extended data: Supplemental Table 1\(^3^\)). Scores in the SF-36 and SF-12 general health and PF domains were predictors of mortality in studies conducted in the Netherlands\(^6\), and the USA\(^6\), and were associated with an increased risk of hospitalization and ED visits in another study in the USA\(^6\). Two further studies, one in Italy\(^6\) and the other multinational\(^6\), found that KCCQ score was a predictor of mortality, and a study in the USA reported a negative association between MLHFQ score and cardiac event-free survival\(^9\). Physical and depressive symptoms, in addition to spiritual well-being and comorbidity count, were negatively correlated with HF-specific health status (partially determined by KCCQ score) in patients in the USA\(^6\). An Australian study examined the contribution of MLHFQ and EQ-5D scores to composite scoring systems in HF trials\(^7\).

**Impact of sociodemographic status on HRQoL in patients with HF**

In several studies, patient ethnicity and sex were shown to impact HRQoL (Extended data: Supplemental Table 1\(^3^\)). A study in the USA found that Hispanic patients reported better HRQoL than those of white or black ethnicity\(^1\). In two Canadian studies, women reported worse physical and overall HRQoL, respectively, than men at baseline\(^3\),\(^2\), and worse physical HRQoL at 12 months\(^2\). Sociodemographic factors including marital status, education, income, and employment were correlated with worse HRQoL in studies in the Netherlands\(^1\) and in Canada, France, and the USA\(^6\).

**Total costs for HF**

The overall costs associated with the treatment for HF varied widely across studies. This is likely to result from disparities in study settings and populations, which meant that the patients included differed in terms of disease severity, clinical history, and comorbidities.
Five studies conducted in Europe reported total annual healthcare costs associated with HF. The lowest annual per-patient costs reported were €3150 in a German study, followed by £5700 in a Swedish study, and €6571 in a study conducted in Spain. Two Italian studies, each of which included only patients who had experienced an HF-related hospitalization, reported total annual costs of €111100 and €11864, respectively.

The lowest total annual costs reported in the USA were for a subpopulation of individuals enrolled in Medicare; patients with HF who were not classed as having a low income or dual eligibility for Medicare and Medicaid (non-low-income/dually eligible [LI/DE] cohort) incurred per-patient costs of US$13 897 annually. This value was US$17 840 for patients with HF who were classed as LI/DE. The highest annual US costs identified were from a study comparing patients with HF who died within 1 year and those who survived. Surviving patients incurred total mean per-patient costs of US$36 426 per annum. A further four US studies reported annual per-patient costs in the range of US$16 912–29 456. Two additional US studies recorded total costs for patients in the period before they died as a result of HF; these data are not included in the overall range, but are presented in Extended data: Supplemental Table 2. In addition to evidence from Europe and the USA, total annual costs associated with HF were reported as C$27 809 in a Canadian study and ¥28 974 in a study from China.

Rather than reporting annual total costs for HF, two studies presented data collected over different time periods (Extended data: Supplemental Table 2). A UK study reported the total costs incurred in the year before an HF event and in the 36 months after the event, and a US study reported total Medicare payments over 30 days for patients discharged from hospital, grouped based on dyspnoea severity.

Costs and resource use for patients with and without HF
Eight studies, all from the USA, compared costs and resource use for patients with HF with those for individuals without HF, or with other chronic diseases. Total annual costs were significantly higher for patients with HF than for those without HF (p<0.001): 4.6 times higher (US$27 152 vs US$5952) during 2010–2011, and 4.3 times higher during 2002–2011 (US$23 854 vs US$5511). A breakdown of constituent costs in this study is shown in Figure 5. Another study compared allowed monthly Medicare costs and resource use for patients with HF and all individuals who made Medicare claims (fee-for-service population). Per-patient allowed monthly costs for HF were 3.2 times higher than those incurred by the average fee-for-service patient (US$3395 vs US$1045). Patients with HF also had comparatively higher rates of inpatient admission, 30-day readmission, and use of skilled nursing facilities, meaning that higher costs were incurred for all of these resources, compared with the Medicare fee-for-service population.

Additional evidence indicated that HF is associated with increased resource use. A study of patients who were admitted to hospital for trauma and subsequently discharged found that the presence of HF was associated with a 71% increased risk of 30-day hospital readmission (24% vs 14%; p<0.0001). An examination of the resource use associated with hospital discharge for patients with HF, compared with all patients discharged, showed that costs for cardiology, supplies and devices, coronary care, and operating room services were 1.3–3.3 times higher for patients with HF. Although few studies focused on indirect costs, one study examining care requirements was identified. In patients aged over 50 years, individuals with HF were significantly more likely than those without HF to make use of either formal (paid) care (HF: 9.1%; no HF: 1.5%; p<0.001) or informal care (HF: 33%; no HF: 8.6%; p<0.001), defined as care provided by a family member or unpaid volunteer. Patients with HF required significantly more informal care per week than those without HF (32.1 hours vs 25.1 hours; p=0.002).

Three studies compared the costs associated with HF and those for other chronic diseases. One study showed that similar total annual costs were associated with HF and obesity (US$1642 and US$1908, respectively); however, these conditions were considerably more costly than hypertension, which was associated with costs of US$431 per annum. A second study reported that total annual costs were nearly twofold higher for HF than for DM, partly owing to higher inpatient and outpatient costs. Finally, a study reporting disease-specific costs showed that HF incurred higher annual medical and pharmacy costs than asthma, coronary artery disease, COPD, DM, hyperlipidaemia, and hypertension.

Costs for HF as a comorbidity
Three studies showed that HF is associated with additional costs in patients with DM. A UK study estimated that annual inpatient care costs for a typical 60-year-old man with type 2 DM are more than six times higher in the presence of HF than if HF does not occur (£3191 for HF vs £459 for no HF). The occurrence of HF in a patient with DM was also estimated to result in 84% higher non-inpatient costs. The cost of preventable hospitalization for HF in patients with DM was reported as US$7949 in a US study, and a second US study found that acute care for an HF episode incurred costs of US$23 758 per event-year, plus US$1904 in ongoing management costs. The impact of HF in obese patients was also examined in one study. Patients with obesity but no HF incurred annual total costs of US$1908; however, this rose to US$2576 in patients with HF as well as obesity.

Two US studies reported the cost impact of comorbidities in patients with HF (Extended data: Supplemental Table 2). Shaya et al. estimated the annual cost savings that could be made via a 20% reduction in a range of comorbidities, the most costly of which were cardiovascular disease and DM. Smith et al. estimated the contribution of various comorbidities to the overall cost of care for patients with HF, finding that DM incurred the greatest costs of the comorbidities examined in the study.

Costs by severity of HF
Only one study, conducted in Japan, reported costs by HF severity. Hospitalization costs were modelled across NYHA classes: compared with NYHA class II, classes III and IV were
associated with an additional US$490 and US$640, respectively (p<0.001).

Costs by HF ejection fraction status
Two Swedish studies collected data on the total annual direct costs associated with HFrEF\textsuperscript{106} and HFpEF\textsuperscript{107}. These studies, however, were not conducted simultaneously or designed to compare costs by ejection fraction, so limited inference should be drawn from across-study comparisons. HFrEF was associated with slightly higher annual costs than HFpEF (€12,447 vs €11,344), as a result of higher costs associated with inpatient care, hospitalizations, and medication. Annual outpatient clinic costs were approximately 43% higher for HFpEF than for HFrEF (€1,561 vs €1,094).

Two US studies compared resource use between patients with HFrEF and those with HFpEF. One study found no significant difference between the two groups in terms of 30-day hospital readmission rate. However, patients with HFrEF had a significantly greater length of stay (LoS) in hospital than patients with HFpEF (HFrEF: 10.9 days; HFpEF: 8.5 days; p=0.027).\textsuperscript{96} In a second study, there were no significant differences between groups in terms of adjusted 30-day readmission rates, annual hospitalization rate, LoS, or pharmaceutical dispenses. Although the absolute differences between cohorts were small, HFpEF was associated with significantly more outpatient visits (HFpEF: 21.5; HFrEF: 20.1; p<0.002) and ED visits (HFpEF: 3.24; HFrEF: 2.94; p<0.002) annually than HFrEF, as well as a significantly higher rate of readmission within 1 year (HFpEF: 58%; HFrEF: 55%; p=0.010).\textsuperscript{108}

Costs for inpatient care and hospitalization in patients with HF
Inpatient care and hospitalization were identified as major cost drivers in HF and were reported as the single largest contributor to costs in multiple studies across different geographies. There was relatively wide variation across studies in the percentage of costs contributed by inpatient care, which can be accounted for by differences between populations and disparities in the types of costs included in each study.
In total, five European studies presented inpatient care or hospitalization as a percentage of total or direct costs: one each from Germany\(^7\), Italy\(^11\), and three from Sweden\(^8,106,107\). Inpatient care or hospitalization contributed 69–87% of total costs in these studies (Extended data: Supplemental Table 3\(^9\)). Ten studies reported relevant data from North America, of which eight were conducted in the USA\(^8,108-110,113\), one took place in Canada\(^8\), and one conducted analyses using data from a clinical trial with study centres in the USA, Canada, and France\(^11\). The percentage of total costs contributed by inpatient or hospitalization costs across these studies varied between 47%\(^8,114\) and approximately 87%\(^8,108,109\) (Extended data: Supplemental Table 3\(^9\)). Three studies included only patients who died from HF; however, the contribution of inpatient care to total costs in these studies fell within the overall range for all studies\(^8,108,111\). An additional US study reported the proportion of total claims for HF accounted for by inpatient claims (60.5%) and outpatient claims (39.5%)\(^9\). One additional study, conducted in China, reported that inpatient care contributed 66% of total costs (Extended data: Supplemental Table 3\(^9\)).

A German study estimated the future costs of inpatient care for HF, predicting that the overall budget impact in Germany would be €1.8 billion in 2025, up from €1.27 billion in 2009\(^12\). This predicted increase arose from a 14% increase in the cost allowance per patient with HF in hospital and a 23% increase in the number of patients with HF in hospital.

Several other studies reported inpatient or hospitalization costs (Extended data: Supplemental Table 2\(^9\)). Seven studies, two from the UK\(^8,116\), and five from the USA\(^8,114-117\), collected data on overall inpatient/hospitalization costs associated with HF; however, these were not reported as a percentage of total costs. Additionally, five US studies reported the costs associated with a single hospitalization\(^8,118-120\), and one reported the cost of an ‘acute HF hospital episode’ as US$107 775\(^12\).

### Hospitalization and readmission rates for patients with HF

Patients’ risk of hospitalization for HF or readmission within 1 year is likely to be influenced by factors such as disease severity, and consequently a wide range of rates were reported across the studies identified. There was a larger evidence base for all-cause 30-day readmission rates; these studies indicated that between 15% and 30% of patients hospitalized for HF are likely to be readmitted within a month after discharge from hospital.

Seven studies\(^7,8,10,82,87,109,111,124\) reported 1-year hospitalization rates (Extended data: Supplemental Table 4\(^9\)). An Italian study found that HF-related and all-cause hospitalization rates were considerably lower in patients who had never been hospitalized for HF than in those who had (HF-related: 0.4% vs 22%; all-cause: 15% vs 59%)\(^8\). All-cause hospitalization was 30.8% in a Spanish study\(^79\). In the USA, HF-related hospitalization rates ranged from 6%\(^82\) to 22%\(^8,109\), and all-cause hospitalization rates ranged from 33% to 57%\(^9\). In a multinational study, 38% of patients experienced all-cause hospitalization\(^114\). A study in China reported relatively high rates of HF-related hospitalization within 1 year, at 34.8%\(^121\). A further 13 studies reported data on hospitalizations (Extended data: Supplemental Table 2\(^9\))\(^8,9,10,8,10,10,10,10,10,10,10,10\), but did not present data as a percentage of patients experiencing hospitalization, did not report rates over 1 year, or included only patients who died of HF.

Studies that reported 1-year hospital readmission rates, of which five were from the USA\(^8,108,113,129,130\), and one each from Italy\(^63\), Australia\(^11\), and China\(^2\), are summarized in Extended data: Supplemental Table 5\(^9\). HF-related readmission rates ranged from 13.8% in a US study\(^130\) to 46.1% in the Italian study\(^63\), and all-cause readmission rates ranged from 55% in the USA\(^108\) to 73% in Australia\(^31\).

Hospital readmission rates at 30 days were reported in studies from the USA, Australia, and China (Extended data: Supplemental Table 6\(^9\)). In the USA, HF-related rates of readmission were 6.4–12.5%\(^8,10,12,129,132,133\), and all-cause rates were 17.1–30.4%\(^6,10,14,14,19-12,129,132,136\). An additional US study reported all-cause 30-day readmission rates after hospital discharge following implantation of an LVAD as 27.6%\(^139\). Similar rates were reported in Australia (HF-related: 11%; all-cause: 27%)\(^131\) and slightly lower rates reported in China (HF-related: 4.1%; all-cause: 16.2%)\(^9\). In addition, a study from Spain reported readmission rates in the 90 or 180 days after discharge from hospital (Extended data: Supplemental Table 2\(^9\))\(^140\).

Two US studies focused on preventable readmissions. Gunadi \textit{et al.} reported results from a care programme intended to reduce readmission rates, showing that the decrease in variable cost for each avoided hospital readmission was US$56 521\(^41\). Chen \textit{et al.} examined the rate of preventable hospital readmissions based on patients’ location and found that those in remote rural areas had a 27% lower risk of 30-day preventable readmission than patients living in urban areas\(^42\).

### Other costs and resource use

A small number of the studies identified reported data that did not fall into any of our key areas of interest (Extended data: Supplemental Table 2\(^9\)). A Spanish study reported prescription drug costs\(^43\), a study from the Netherlands reported care home and nursing home costs for patients at the end of life\(^44\), and three North American studies reported hospital LoS\(^38\), nursing contacts\(^45\), and the association between heart rate and medical costs in patients with HF\(^46\), respectively.

### Discussion

Given the breadth of the evidence identified and the differences in methodology, health technologies and countries in which studies were conducted, we provide an overview of the humanistic and economic impact of HF, intended to supplement the published literature.

### Key findings - HRQoL

The evidence identified in this SR illustrates that HF is associated with a substantial humanistic burden. For the purposes of this review, we consider humanistic burden to represent...
the impact of HF on the individual affected, as indicated by patient-reported outcomes. Patients with HF experience worse HRQoL than both individuals without HF and patients with other chronic diseases, and the burden of HF is greater for patients with more severe disease than for those at earlier stages. Poor mental health, comorbidities, and hospitalization are likely to be associated with worse HRQoL in patients with HF, whereas appropriate disease intervention can help to bring about improvements in HRQoL. This is supported by evidence that HRQoL decreases over time in the absence of disease management, but for patients who were provided support, HRQoL increased over time. Taken together with evidence indicating the positive impact of disease management and self-care, and structured support, this indicates possible ways of improving HRQoL for patients with HF.

Key findings – costs and resource use

The majority of the economic studies identified in this SR were conducted in the USA, with a smaller evidence base in Europe and relatively few studies from the rest of the world. HF is associated with considerable healthcare costs, and patients with HF incur higher costs and greater resource use, including inpatient, outpatient, and informal care, than individuals without HF or with other chronic diseases. The occurrence of HF as a comorbidity is also associated with extra costs. There is evidence to indicate that costs rise with increasing severity of HF, although this is based on only one study. The results of studies reporting costs and resource use by ejection fraction were mixed and did not provide sufficient evidence to conclude whether HFrEF or HfPEF incurs higher costs. As the diagnosis of HF has previously hinged on EF, with therapy development focused on reduced EF, limited evidence may be available on the treatment of HfPEF\(^\text{15}\). Patients with HF are at a relatively high risk of hospitalization or readmission; accordingly, inpatient care and hospitalizations were identified as key cost drivers.

Several studies suggested that improved disease management, with the aim of reducing the number of inpatient cases and reducing patients’ risk of hospital readmission, could be a way to limit the economic impact of HF. Specific strategies discussed included use of case-management programmes, identification of risk factors for readmission, and optimization of medication, for example by improving adherence.

Evidence gaps

This SR identified a broad range of studies; consequently, this review has focused on key areas of interest that best illustrate the impact of HF. Some studies have been presented in less detail, either because they did not discuss these key themes or because the data reported were not readily comparable with the rest of the evidence base, owing to differences in study population, setting, or time frame.

Although a large number of studies were identified, some gaps in the evidence base were apparent. In studies comparing patients with HF and individuals with other chronic conditions, disease severity in the individual patient populations was not specified, nor was the impact of treatment interventions over the period of the study. This is particularly relevant when comparing different diseases, for which the effect of treatment upon HRQoL may vary considerably. Further studies on HRQoL in patients with HF, particularly those assessing the incremental effects of the disease over time or with increasing severity, would be valuable as part of an overall approach to identify means of improving patients’ well-being.

A relatively small number of studies that assessed the economic impact of HF included detailed clinical information. The majority of studies in this SR, particularly those from the USA, which was the country with the largest evidence base, identified patients with HF in administrative claims databases using International Classification of Diseases diagnosis codes. This meant that factors such as comorbidities, HF severity by NYHAA classification, and disease history were not known for all patient populations. These factors can have a large impact on disease outcomes and associated costs; therefore, some of the variation between the costs reported in different studies is likely to be attributable to factors that are not recorded. Economic studies in which patients’ medical records are available might therefore be valuable to obtain more granular data on cost drivers in HF. In addition, there is little published information on the indirect costs associated with HF, with very few studies reporting data on informal care for patients with HF; thus, the wider societal impact of the disease is not immediately apparent in the literature.

Limitations

The design and scope of this SR meant that it is possible that not all relevant evidence was identified. Restrictions were applied to the evidence identified in the initial searches, by patient numbers, HRQoL instrument, and type of study. In particular, the restriction to economic studies including at least 100 patients and humanistic studies including at least 200 patients may have skewed the SR toward studies using patient registries and administrative claims data. Therefore, any studies with smaller sample sizes that included detailed clinical data for patients would not have been examined within the scope of the review. A formal assessment of the studies included was not carried out as part of the review process. This would typically include evaluation of each study’s inclusion criteria, measurement methods, analytic methods, and risk of bias\(^\text{148}\). Although all evidence discussed here is of value to address our research question, such an assessment might have highlighted any studies that were of particularly high or low quality, and helped to explain any major differences between the trends reported in different studies.

Conclusions

Our findings indicate that both the humanistic and economic burden is increased in patients with HF compared with individuals without HF. Quantification of the detriment experienced by patients with HF is challenging owing to the heterogeneity of the study population and methodology employed as well
as inherent differences between health systems and costs in different countries. However, there is overarching evidence to suggest that the burden of disease increases as disease worsens. Inpatient care and hospitalization costs were identified as key economic drivers.

It appears that slowing or preventing HF progression is likely to improve patients’ overall well-being, a healthcare aim that is particularly important given the substantial and increasing humanistic burden experienced by patients with HF. Reduction in patients’ hospitalization rates, and limiting the overall requirement for inpatient care, is the healthcare goal that would have the greatest impact on the economic burden of HF. The evidence that we have identified suggests that early treatment of HF to prevent or to delay disease progression, as well as careful disease management to avoid or lessen the need for hospital admission, is likely to lessen the humanistic burden and economic impact of HF.

Data availability
Underlying data
All data underlying the results are available as part of the article (included under extended data), and no additional source data are required to support our results.

Extended data
figshare: Supplemental content 1 – Supplemental Table 1, http://doi.org/10.6084/m9.figshare.8099915.
figshare: Supplemental content 2 – Supplemental Tables 2–6, http://doi.org/10.6084/m9.figshare.8099969.

The systematic review protocol is available on request by contacting the corresponding author.

Reporting guidelines
PRISMA checklist: figshare: Supplemental Content 3 – PRISMA checklist, http://doi.org/10.6084/m9.figshare.8100020.

References
1. Roger VL: Epidemiology of heart failure. Circ Res 2013; 113(6): 646–59. PubMed Abstract | Publisher Full Text | Free Full Text
2. Van Bakel AB, Chldsey G: Management of advanced heart failure. Clin Cornerstone. 2002; 4(6): 42–52. PubMed Abstract | Publisher Full Text
3. Ahmed A, Campbell RC: Classes of heart failure: existing measures and future uses. Heart Fail Clin. 2015; 10(3): 236–46. PubMed Abstract | Publisher Full Text
4. MacMahon KM, Lip GY: Psychological factors in heart failure: a review of the literature. Arch Intern Med. 2002; 162(5): 509–16. PubMed Abstract | Publisher Full Text
5. Redekop WK, Koopmanschap MA, Stolk RP: Disease monitoring of patients with chronic heart failure. Heart. 2007; 93(4): 519–23. PubMed Abstract | Publisher Full Text | Free Full Text
6. Heo S, Lennie TA, Okoli C, et al.: Quality of life in patients with heart failure: ask the patients. Heart Lung. 2009; 38(2): 100–8. PubMed Abstract | Publisher Full Text | Free Full Text
7. Macdonald IA, Campbell GC, Lee DS, et al.: Improving care for patients with heart failure: before, during and after hospitalization. Eur Heart Fail. 2014; 16(2): 110–45. PubMed Abstract | Publisher Full Text
8. Ochalski N, Vest AR, Cohen JT, et al.: Cost comparison across heart failure patients with reduced and preserved ejection fractions: analyses of inpatient uncompensated heart failure admissions. In J Cardiol. 2018; 261: 103–8. PubMed Abstract | Publisher Full Text
9. Ochalski N, Vest AR, Cohen JT, et al.: Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovasc Diabetol Metab. 2020; 9(1): 17–23. PubMed Abstract | Publisher Full Text | Free Full Text
10. Mithal M, Mann WC, Stone JH: Functional limitation and disability associated with congestive heart failure. Phys Occup Ther Geriatr. 2001; 18(3): 45–56. Publisher Full Text
11. MacMahon KM, Lip GY: Psychological factors in heart failure: a review of the literature. Arch Intern Med. 2002; 162(5): 509–16. PubMed Abstract | Publisher Full Text
12. Schoenmaker CJ, van Dijk JP, Schurgers H, et al.: Impact of heart failure on quality of life: a systematic review of the literature. Eur J Cardiothorac Surg. 2007; 31(5): 939–46. PubMed Abstract | Publisher Full Text | Free Full Text
13. Nicholls MG, Richards AM: Christchurch Cardioendocrine Research Group: Disease monitoring of patients with chronic heart failure. Heart. 2007; 93(4): 519–23. PubMed Abstract | Publisher Full Text | Free Full Text
14. Ahmed A, Campbell RC: Classes of heart failure: existing measures and future uses. Heart Fail Clin. 2015; 10(3): 236–46. PubMed Abstract | Publisher Full Text
15. Macdonald IA, Campbell GC, Lee DS, et al.: Improving care for patients with heart failure: before, during and after hospitalization. Eur Heart Fail. 2014; 16(2): 110–45. PubMed Abstract | Publisher Full Text
16. Ochalski N, Vest AR, Cohen JT, et al.: Cost comparison across heart failure patients with reduced and preserved ejection fractions: analyses of inpatient uncompensated heart failure admissions. In J Cardiol. 2018; 261: 103–8. PubMed Abstract | Publisher Full Text
17. Ochalski N, Vest AR, Cohen JT, et al.: Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovasc Diabetol Metab. 2020; 9(1): 17–23. PubMed Abstract | Publisher Full Text | Free Full Text
18. Mithal M, Mann WC, Stone JH: Functional limitation and disability associated with congestive heart failure. Phys Occup Ther Geriatr. 2001; 18(3): 45–56. Publisher Full Text
19. MacMahon KM, Lip GY: Psychological factors in heart failure: a review of the literature. Arch Intern Med. 2002; 162(5): 509–16. PubMed Abstract | Publisher Full Text
and costs of care: a network analytic approach to care coordination using claims data. J Gen Intern Med. 2013; 28(3): 459–63.

83. Obi EN, Swindle JP, Turner SJ, et al.: Health care costs for patients with heart failure escalate nearly 3-fold in final months of life. J Manag Care Spec Pharm. 2016; 22(12): 1446–57.

84. Unroe K, Melissa G, Johnson KS, et al.: Racial differences in hospice use and end of life care among medicare beneficiaries with heart failure. J Am Geriatr Soc. 2011; 59: 58–59.

Reference Source

85. Giles L, Freeman C, Field P, et al.: figshare: Supplemental content 2 – Supplemental tables 2-6. http://www.doii.org/10.6084/m9.figshare.8099969

86. Wijeyasurya HC, Austin PC, Wang X, et al.: The effect of multidisciplinary heart failure clinic characteristics on 1-year postdischarge health care costs: a population-based study. Med Care. 2014; 52(3): 272–9.

87. Pollack CE, Weissman GE, Lemke KW, et al.: Patient sharing among physicians and costs of care: a network analytic approach to care coordination using claims data. J Gen Intern Med. 2013; 28(3): 459–63.

88. Hoekstra T, Jaarsma T, van Veldhuisen DJ, et al.: Network of Nurses of GISS-HF, Di Giulio P: Should patients perception of heart status be included in the prognostic assessment of heart failure patients? A prospective study. Qual Life Res. 2014; 23(1): 49–56.

89. Kosiborod M, Soto GE, Jones PG, et al.: Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007; 115(15): 1975–81.

90. Wu JR, Lennie TA, Frazier SK, et al.: Health-related quality of life, functional status, and cardiac event-free survival in patients with heart failure. J Cardiovasc Nurs. 2016; 31(3): 236–44.

91. Lum HD, Carey EP, Fairclough D, et al.: Burdensome physical and depressive symptoms predict specific health status over one year. J Pain Symptom Manage. 2016; 51(6): 963–70.

92. Chang S, Davidson PM, Newton PJ, et al.: Composite outcome measures in a pragmatic clinical trial of chronic heart failure management: a comparative assessment. Int J Cardiol. 2015; 185: 62–8.

93. Riegel B, Moser DK, Rayens MK, et al.: Economic burden of heart failure in China: impact on disease management and resource utilization. J Med Econ. 2017; 20(5): 549–53.

94. Mentz RJ, Me K, Sharma PP, et al.: Relation of dyspnea severity on admission for acute heart failure with in-hospital mortality and costs. Am J Cardiol. 2015; 115(1): 75–81.

95. Fitch K, Pelizzari PM, Pyerson B: Inpatient utilization and costs for Medicare fee-for-service beneficiaries with heart failure. Am Heart Drug Benefits. 2016; 9(2): 96–104.

96. Alkhawam H, Madarneh R, El-hunjul M, et al.: Morbidity and mortality of congestive heart failure in trauma patients. Am J Med Sci. 2016; 352(2): 172-6.

97. Danese MO, Gleeson M, Kutikova L, et al.: Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. 2016; 6(8): e011805.

98. Biermann J, Neumann T, Angermann CE, et al.: Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. J Med Econ. 2017; 20(5): 549–53.

99. Mentz RJ, Me K, Sharma PP, et al.: Relation of dyspnea severity on admission for acute heart failure with in-hospital mortality and costs. Am J Cardiol. 2015; 115(1): 75–81.

100. Fitch K, Pelizzari PM, Pyerson B: Inpatient utilization and costs for Medicare fee-for-service beneficiaries with heart failure. Am Heart Drug Benefits. 2016; 9(2): 96–104.

101. Ward A, Alvarez P, Vo L, et al.: What hospital inpatient services contributed the most to the 2001-2006 growth in the cost per case? Health Serv Res. 2012; 47(5): 1814-35.

102. Padula WW, Allen RR, Nair KV: Determining the cost of obesity and its common comorbidities from a commercial claims database. Clin Obes. 2014; 4(1): 53–8.

103. Danese MO, Gleeson M, Kutikova L, et al.: Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. 2016; 6(8): e011805.

104. Fitch K, Pelizzari PM, Pyerson B: Inpatient utilization and costs for Medicare fee-for-service beneficiaries with heart failure. Am Heart Drug Benefits. 2016; 9(2): 96–104.

105. Padula WW, Allen RR, Nair KV: Determining the cost of obesity and its common comorbidities from a commercial claims database. Clin Obes. 2014; 4(1): 53–8.

106. Smith DH, Johnson ES, Blough DK, et al.: Predicting costs of care in heart failure patients. BMC Health Serv Res. 2012; 12: 434.

107. Sasaki N, Kunisawa S, Ikai H, et al.: Differences between determinants of in-hospital mortality and hospitalisation costs for patients with acute heart failure: a nationwide observational study from Japan. BMJ Open. 2017; 7(3): e013753.

108. Ward A, Alvarez P, Vo L, et al.: Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014. 17(3): 176-83.

109. Shaya FT, Breunig IM, Mehr OA: Disease-modifying therapy and hospitalization risk in heart failure patients. Am J Manag Care. 2015; 21(8): 440–50.

110. Alka ML, Gray A, Mihaylova B, et al.: The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015; 32(4): 459–66.

111. Chen HF, Popoola T, Radhakrishnan K, et al.: Improving diabetic patient transition to home health care: leading risk factors for 30-day readmission. Am J Manag Care. 2015; 21(8): 440–50.

112. Wang J, Feng J, Losby JL, et al.: Differences between determinants of in-hospital mortality and hospitalisation costs for patients with acute heart failure: a nationwide observational study from Japan. BMJ Open. 2017; 7(3): e013753.

113. Smith DH, Johnson ES, Blough DK, et al.: Predicting costs of care in heart failure patients. BMC Health Serv Res. 2012; 12: 434.

114. Biermann J, Neumann T, Angermann CE, et al.: Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. J Med Econ. 2017; 20(5): 549–53.
utilization in patients with heart failure and preserved versus reduced ejection fraction. Am J Cardiol. 2015; 116(7): 1088-92.

109. Reed SD, Li Y, Ellis SJ, et al.: Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION. J Card Fail. 2012; 18(10): 784-91.

110. Voigt J, Sasha John A, Taylor A, et al.: A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Cardiol. 2014; 37: 312-21.

111. Li Y, Levy WC, Neilson MP, et al.: Associations between Seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION. J Card Fail. 2014; 20(8): 541-7.

112. Smidt S, Hendricks V, Griebenov R, et al.: Demographic change and its impact on the health-care budget for heart failure inpatients in Germany during 1995-2025. Herz. 2013; 38(8): 862-7.

113. Reed SD, Li Y, Dunlap ME, et al.: In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol. 2012; 110(8): 1150-5.

114. Amin A, Deitelzus S, Christian R, et al.: Healthcare resource burden associated with hypertension among patients hospitalized for heart failure in the US. J Med Econ. 2013; 16(3): 415-20.

115. Corbisiero R, Buck DC, Muller D, et al.: What is the cost of non-response to cardiac resynchronization therapy? Hospitalizations and healthcare utilization in the CRT-D population. J Interv Card Electrophysiol. 2016; 47(2): 189-95.

116. Bress AP, King JB, Brimer D, et al.: Pharmacotherapy treatment patterns, outcomes, and health resource utilization among patients with heart failure with reduced ejection fraction at a U.S. academic medical center. Pharmacotherapy. 2016; 36(2): 174-86.

117. Dunlap SM, Redfield MM, Jiang R, et al.: Heart failure hospitalizations in the Hunter New England area over 10 years. A changing trend. Heart Lung Circ. 2017; 26(6): 627-30.

118. Donal E, Lund LH, Oger E, et al.: New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Kar (Karlońska) Ren (Rennes) Study. Eur J Heart Fail. 2015; 17(7): 680-8.

119. Dunlay SM, Redfield MM, Jiang R, et al.: Care in the last year of life for community patients with heart failure. Circ Heart Fail. 2015; 8(3): 489-96.

120. Munir MB, Sharbaugh MS, Thoma PW, et al.: Trends in hospitalization for congestive heart failure, 1996-2009. Clin Cardiol. 2017; 40(2): 109-19.

121. Cooper LB, Hammill BG, Sharma PP, et al.: Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. Am Heart J. 2015; 170(6): 1124-32.

122. Sánchez J, Wheatley M, Georgioupolou V, et al.: Favorable bed utilization and readmission rates for emergency department observation unit heart failure patients. Acad Emerg Med. 2013; 20(6): 554-61.

123. Robertson J, McDuff P, Pearson SA, et al.: The health services burden of heart failure: an analysis using linked population health data-sets. BMC Health Serv Res. 2012; 12: 103.

124. Arora S, Patel P, Lahewala S, et al.: Etiologies, trends, and predictors of 30-day readmission in patients with heart failure. Am J Cardiol. 2017; 119(5): 760-9.

125. Krumholz HM, Chaudhry SI, Spurgeon JA, et al.: Do non-clinical factors improve prediction of readmission risk?: Results from the Tele-HF study. JACC Heart Fail. 2016; 4(1): 12-20.

126. Kociol RD, Liang L, Hernandez AF, et al.: Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Am Heart J. 2013; 166(6): 987-94.e1.

127. Perkins RM, Rahman A, Bucaiuolo ID, et al.: Readmission after hospitalization for heart failure among patients with chronic kidney disease: a prediction model. Clin Nephrol. 2013; 80(3): 133-40.

128. Sun-dun SM, Haas LR, Herrin J, et al.: Use of post-acute care services and readmissions after left ventricular assist device implantation in privately insured patients. J Card Fail. 2015; 21(10): 816-23.

129. Franco J, Formiga F, Trullas JC, et al.: Impact of prealbumin on mortality and hospital readmission in patients with acute heart failure. Eur J Intern Med. 2017; 43: 36-41.

130. Gunadi S, Upfield S, Pham ND, et al.: Development of a collaborative transitions-of-care program for heart failure patients. Am J Health Syst Pharm. 2015; 72(13): 1147-52.

131. Chen HJ, Carlson E, Popoola T, et al.: The impact of rurality on 30-day preventable readmission, illness severity, and risk of mortality for heart failure Medicare home health beneficiaries. J Rural Health. 2016; 32(2): 176-87.

132. van der Riet AG, Ooster-Veld MG, Paxman HR, et al.: Relating cause of death with place of care and healthcare costs in the last year of life for patients who died from cancer, chronic obstructive pulmonary disease, heart failure and dementia: a descriptive study using registry data. PloS Med. 2017; 14(6): 383-40.

133. Radhakrishnan K, Jacelon CS, Bigelow C, et al.: Association of comorbidities with home care service utilization of patients with heart failure while receiving telehealth. J Cardiovasc Nurs. 2013; 28(3): 216-27.

134. Pevere AD, Schulte PJ, Ments RJ, et al.: Relation of elevated heart rate in patients with heart failure with reduced ejection fraction to one-year outcomes and costs. Am J Cardiol. 2016; 117(6): 946-51.

135. Everoli MA, Shah AM, Borlaug BA: Heart failure with preserved ejection fraction in perspective. Circ Res. 2019; 124(1): 1598-617.

136. Pfeffer MA, Shah AM, Borlaug BA: Heart failure with preserved ejection fraction in perspective. Circ Res. 2019; 124(1): 1598-617.

137. Sanderson S, Tatt TD, Higgins JP: Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007; 36(3): 666-76.

138. Friedman C, Field P, et al.: Figshare: Supplemental content 3 – PRISMA checklist. http://www doi.org/10.6084/m9.figshare.8100020
Open Peer Review

Current Peer Review Status:  

✓

Version 2

Reviewer Report 03 September 2020

https://doi.org/10.5256/f1000research.28587.r69776

© 2020 Wikström G. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gerhard Wikström
Department for Medical Sciences, Uppsala University, Uppsala, Sweden

I am now satisfied with the responses from the authors and think the paper can be accepted for indexing.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 18 May 2020

https://doi.org/10.5256/f1000research.21228.r62538

© 2020 Wikström G. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gerhard Wikström
Department for Medical Sciences, Uppsala University, Uppsala, Sweden

The results are well presented and the underlying material is impressive. This is a paper dealing with the quality of life and costs for patients with heart failure the data are extracted from databases, three types. Economic burden is readily understood but “humanistic burden”, how is that measured and defined? The study refers to health-related quality of life measurements of three different types. In
total 124 studies were found dealing with the two types of outcomes that the study was looking for. Prognosis, quality of life, and costs relevant parameters for patients with heart failure. All three are well known and with discouraging results in several previous studies. The novelty in this paper is debatable since no new conclusions are drawn from the results. Only passive observations so common in this type of statistical work.

Why do the authors use the expression humanistic burden? It is not well defined and can be substituted for suffering, mental stress, low QoL etc. The last sentence in the first part of the discussion should be emphasized in order to justify the amount of statistics and work put down in this paper.

In the discussion part about cost and resource use, the authors conclude with suggestions on how to reduce the increasing cost for HF management. Both the conclusions for increasing QoL and how to reduce the costs are very similar. Should that not stimulate the authors for more distinct conclusions about the interpretation of their findings?

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Partly

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I am a collaborator in two referred papers in the reference list

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 03 Aug 2020

Bernt Kartman, PharmaGenesis Oxford Central, Oxford, UK

We would like to thank Professor Wikström for taking the time to read and review and for his valuable contributions. We have taken on board Professor Wikström’s feedback and implemented it in the following ways:

○ We have further defined the term humanistic burden as used in the context of this article both in the introduction and in the discussion
○ In the discussion, we have highlighted that, given the breadth of this review, a formal assimilation of the data identified is challenging and that we have therefore provided a narrative overview of the evidence identified, which was intended to supplement
other published reviews

- We have amended the conclusions to include the challenges of drawing specific conclusions from such wide-reaching studies and provided some overarching conclusions; however, given the disparate nature of the evidence base, care should be taken in drawing definitive conclusions.

**Competing Interests:** Bernt Kartman and Elisabeth Sörstadius are both employees of AstraZeneca Gothenburg, Mölndal, Sweden. Lucia Giles, Caroline Freeman, and Polly Field are employees of PharmaGenesis Oxford Central, Oxford, UK and were funded by AstraZeneca for systematic review and medical writing support.

Reviewer Report 19 July 2019

https://doi.org/10.5256/f1000research.21228.r50955

© 2019 McGee M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Michael McGee
University of Newcastle, Newcastle, NSW, Australia

Overall, this article is a systematic review of the economic and personal burden of heart failure. The authors have preformed an admirably and extensive task given the scope of the project. The size and scope of the project limits it's utility, given the lack of bias assessment for each article and lack of clarity comparing outcomes and healthcare costs across vastly different healthcare systems.

Introduction:
Doesn't provide background on previous estimated or quality of life reviews regarding HF. Does not compare HF to those of any other chronic disease process (such as renal failure, respiratory disease etc.). Nor does it explain the significant differences in HFpEF and HFrEF from an economic perspective.

Methods:
Not registered prospectively.

Results:
Well presented given the wide reaching scope of the review.

Discussion:
Reasonable discussion. Should be noted that patients with HFpEF have limited treatment options and they're major mortality drivers are usually non-cardiac.
Conclusions:
The authors conclude "Our findings indicate that patients with HF experience a greater humanistic burden and incur higher economic costs than individuals without HF or patients with other chronic diseases" and this conclusion is outside the reach of the review and would be better worded: "Our findings indicate that patients with HF experience a greater humanistic burden and incur higher economic costs than individuals without HF" as there is insufficient scope to comment on other chronic diseases.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cardiology, perioperative medicine, indigenous health, cardiac implantable electronic devices

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 03 Aug 2020

Bernt Kartman, PharmaGenesis Oxford Central, Oxford, UK

We would like to thank Dr McGee for taking the time to read and review our article and for his valuable contributions. We have taken on board Dr McGee's feedback and implemented it in the following ways:

- We have distinguished between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the introduction, noting the differences in aetiology and disease progression. We have also introduced discussion of the limited treatment options in patients with HFpEF compared with those with HFrEF
- We thank Dr McGee for noting that a risk of bias assessment was not performed and the review was not prospectively registered, and that this is a limitation of our research. We have highlighted this in the methodology section and would like to note that the protocol is available on request from the authors
- We have introduced the negative impact of HF on patients' HRQoL relative to other chronic diseases and health individuals as well as the importance of surveying and...
quantifying the impact of heart failure on the patient using patient-reported outcomes. With regard to the conclusions drawn, we identified some evidence that compared HRQoL in patients with HF and those with chronic disease; however, we agree that this was not sufficient to support our conclusions and we amended them as you suggest

- We have also clarified that the wide range of outcomes and healthcare costs identified in our review limits the ability to draw to a clear conclusion from the evidence presented

**Competing Interests:** Bernt Kartman and Elisabeth Sörstdius are both employees of AstraZeneca Gothenburg, Mölndal, Sweden. Lucia Giles, Caroline Freeman, and Polly Field are employees of PharmaGenesis Oxford Central, Oxford, UK and were funded by AstraZeneca for systematic review and medical writing support.